Blood cleansing treatment: what are TPE, INUSpheresis, EBO2 and dialysis?
These procedures share a label but not a mechanism. TPE discards plasma for donor-derived fluid, INUSpheresis filters your own plasma and returns it, dialysis treats kidney failure, and EBO2 exposes blood to ozone. TPE and dialysis are established for specific diseases, aging and pollutant studies measured only blood markers, and a long COVID trial found no benefit.
Nov 17, 2026Updated Nov 18, 20268 min read

"Blood cleansing" is a marketing label for procedures that work in very different ways. Therapeutic plasma exchange (TPE) removes plasma and replaces it, INUSpheresis filters plasma and returns it, dialysis filters wastes and water for failing kidneys, and EBO2 exposes blood to ozone. TPE and dialysis have established uses for specific diseases, but none of these has shown clinical benefit for detox or slowing aging.
What treatments get sold as "blood cleansing"?
Seven procedures commonly carry the label, and only some of them remove anything from the blood. Two, plasma donation and platelet-rich plasma (PRP), are not cleansing treatments at all.
| Treatment | What it does | Status |
|---|---|---|
| Therapeutic plasma exchange (TPE) | Removes plasma and replaces it with a substitute fluid from donors | Evidence graded disease by disease by ASFA |
| INUSpheresis / double-filtration plasmapheresis (DFPP) | Passes plasma through a second filter and returns it | Early pollutant data only |
| EBO2 / EBOO ozone therapy | Exposes blood to ozone | One small trial, in a disease |
| Hemodialysis | Filters wastes and water when kidneys fail | Established for kidney failure |
| Young-donor plasma infusion | Adds plasma from young donors | FDA: "no proven clinical benefit" for aging or memory loss |
| Plasma donation | Collects plasma from healthy donors to make medicines | Not a treatment for the donor |
| Platelet-rich plasma (PRP) | Concentrates platelets from your own blood | Not a cleansing treatment |
EBO2, also written EBOO, has little published evidence. A published controlled trial randomized 28 patients with peripheral artery disease to EBOO or intravenous prostacyclin and appeared in 2005. That trial did not study healthy people or aging. A federal regulation states that "Ozone is a toxic gas with no known useful medical application in specific, adjunctive, or preventive therapy." The rule, part of the FDA's device labeling regulations, treats ozone-generating devices as adulterated or misbranded when used in a medical condition without proof of safety and effectiveness.
How do plasma exchange and INUSpheresis differ?
TPE discards your plasma and replaces it with a donor-derived fluid such as albumin. INUSpheresis and double filtration keep your plasma, pass it through a second filter, and return it to you.
In TPE, a machine separates liquid plasma from blood cells. The American College of Rheumatology (ACR) explains that the plasma, "which contains harmful antibodies, is discarded and replaced with a substitute fluid liquid from donors," and the cells go back to the patient. Next Health says the removed plasma is replaced with sterile albumin solution. For rheumatic diseases, the ACR describes treatment usually every 2 to 3 days over 5 to 10 sessions. That schedule is for disease, not longevity. More detail is in the explainer on how therapeutic plasma exchange works.
Ayus Medical Group, which runs certified INUSpheresis centers, describes plasma being separated from the blood cells by a primary filter and passed through a secondary filter, then remixed with the cells and returned. Its brochure says what is removed "depends on the filter, its pore size and the combination with other filters". Ayus also says its filters are "adapted to your treatment goals" and that "pathogenic substances are filtered out." Those are company claims; the research behind them is covered in the next section. For a fuller comparison, see INUSpheresis vs plasma exchange in detail.
Does blood cleansing slow aging, remove toxins, or help Alzheimer's or long COVID?
Not on current evidence. The strongest support is for specific diseases. The aging and pollutant studies measured blood markers rather than lifespan or health, and a controlled long COVID trial found no benefit.
Established
The American Society for Apheresis (ASFA) grades apheresis disease by disease. Its current edition has 93 fact sheets and 183 graded indications, including rheumatic diseases where harmful antibodies are removed. Dialysis is the established treatment for kidney failure.
Emerging, with limits
- Biological age: An Aging Cell trial randomized 42 healthy adults over 50 to biweekly TPE with or without intravenous immunoglobulin (IVIG), monthly TPE, or placebo, and reported 15 epigenetic clocks showing "rejuvenation" compared with placebo. Epigenetic clocks are blood-based biomarkers; the trial did not measure lifespan or disease. Randomization was based on entry date. Three authors are members of Circulate Inc., and its co-founder and chief science officer also lists an affiliation with Global Apheresis, a clinic that sells TPE series.
- Alzheimer's: The Grifols-funded AMBAR trial randomized 347 patients. It reported 52% less decline on one daily-functioning scale (ADCS-ADL, P = .03), only a trend on a cognitive scale (P = .06), and no changes in patients with mild disease. Six authors were full-time Grifols employees, and the paper concludes that "further studies are warranted."
- Microplastics: A 2026 study measured 114 patients before and after 174 TPE procedures and found circulating microplastics fell. The paper notes that microplastics leach back into the blood from the plastic apheresis tubing, which obscured the reduction in patients with low starting levels. Its authors, mostly affiliated with Circulate Health, state there is "currently no established method" for removing microplastics from the body.
- PFAS: A preliminary double filtration study whose authors include Ayus staff and an advisory board member found decreases in PFAS and microplastics, but responses varied across individuals and analytes, and the authors call for larger, well-designed trials. In a randomized trial of firefighters, regular plasma and whole blood donations significantly reduced PFAS levels, so ordinary donation lowered the number too.
Negative
In a long COVID trial, 50 people received six sessions of TPE or a sham procedure, with no differences between groups in any efficacy measure. The authors wrote that TPE was safe but "did not lead to any discernible improvement."
Unproven or marketing-only
Next Health says plasma is where "microplastics, environmental toxicants, and disease-associated proteins like beta-amyloid accumulate over decades". No study above shows that removing them improves health. The company also writes that plasma exchange, "being FDA-approved for other conditions, is being used off-label" for groups including longevity clients. What the FDA has cleared are machines: the Spectra Optia system was found "Substantially Equivalent" in 2007, and the Amicus separator was cleared for use in therapeutic plasma exchange in 2012. Clearance covers the device, not anti-aging or detox use.
What are the side effects and risks?
TPE is generally well tolerated, but it is not trivial, particularly for people with anemia, those on regular medications, or anyone who needs a central line. During treatment, patients may feel cold, nauseated or tingly in the lips, hands or feet, and fatigue afterward is common.
The ACR notes that TPE can make existing anemia worse. Very rarely it causes light-headedness or fainting, low calcium, vomiting, low blood pressure or muscle cramps. A central line carries a small risk of infection and bleeding, and TPE can remove some medications, including IV drugs. In the Aging Cell trial, the authors report "only two adverse events requiring discontinuation and one related to IVIG". A fuller account is in plasma exchange side effects and how dangerous it is.
What does blood cleansing cost?
TPE prices run from USD 3,500 for one low-volume session to tens of thousands of dollars for multi-session packages, and INUSpheresis is listed at about EUR 2,700 to 2,900 per session in Europe. These figures come from Northvane's clinic listings, checked on 18 November 2026, in no particular order and not as a ranking.
| Clinic | Treatment | Price |
|---|---|---|
| Apeiron Center | Low-volume TPE (1 liter) | USD 3,500 per session |
| Neuroveda Health | TPE | USD 5,000 per session |
| Extension Health | TPE | USD 12,000 per session |
| Global Apheresis | TPE series | USD 15,000 (2), 28,000 (4), 40,000 (6) |
| MDLifespan | TPE protocols | USD 5,995 to 59,995 |
| Biologicum Hamburg | INUSpheresis | EUR 2,900 per session |
| ELLANN Health | INUSpheresis, two treatments | EUR 5,400 to 5,700 |
For how series pricing adds up, see what plasma exchange costs.
Who is blood cleansing for, and what should you ask a clinic?
The evidence is strongest for people with a specific condition that ASFA has graded, treated by a physician who knows their history. For healthy people seeking longevity or detox, the evidence stops at blood markers.
Some providers say as much. Reborne Longevity stated that it does not offer plasma exchange as a treatment for healthy ageing and has since entered administration. Next Health, which offers TPE for wellness, says "no claims are made as to whether this therapy is going to cure or treat any particular disease." Whether you are weighing treatment for yourself or a parent, anemia, regular medications and existing conditions are reasons to talk with your own physician first.
Questions to ask a clinic:
- Which ASFA indication, if any, applies to my condition, and how is it graded?
- Is this plasma exchange or filtration, and what replacement fluid do you use?
- Which device do you use, and what was it FDA-cleared for?
- Will I need a central line, and who places and manages it?
- How will you handle my medications around each session?
- What outcome will you measure, and what does the study you cite actually show?
- Do you or your physicians have ties to any study or company you mention?
Common questions
How long does each session take?
The ACR describes TPE sessions for rheumatic diseases as lasting a few hours. Ayus says an INUSpheresis session takes about 2 to 3 hours. Dialysis is a different commitment: for kidney failure it usually runs about 4 hours, three times a week, on an ongoing basis.
Can you get young-donor plasma infusions for anti-aging?
Some businesses have sold them, but in 2019 the FDA warned consumers that plasma is not approved for aging or memory loss. It listed infectious, allergic, respiratory and cardiovascular risks, including anaphylaxis and transfusion-related acute lung injury, and noted costs of up to thousands of dollars per infusion. This adds someone else's plasma, unlike TPE.
Sources19 cited
- [1]Plasma Exchange (Plasmapheresis) | American College of Rheumatology · rheumatology.org
- [2]63e3de110a90b13e8c33441c_AYUS_This_is_How_Blood_Plasma_Purification_Therapy_Works.pdf · uploads-ssl.webflow.com
- [3]Hemodialysis - NIDDK · niddk.nih.gov
- [4]disease by disease by ASFA · doi.org
- [5]Extracorporeal blood oxygenation and ozonation (EBOO): a controlled trial in patients with peripheral artery disease. · pubmed.ncbi.nlm.nih.gov
- [6]Important Information about Young Donor Plasma Infusions for Profit | FDA · fda.gov
- [7]Plasma FAQs - PPTA · pptaglobal.org
- [8]21 CFR § 801.415 - Maximum acceptable level of ozone. | Electronic Code of Federal Regulations (e-CFR) | US Law | LII / Legal Information Institute · law.cornell.edu
- [9]Therapeutic Plasma Exchange (TPE) · Next Health · next-health.com
- [10]42 healthy adults over 50 · doi.org
- [11]A randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer's disease: Primary results of the AMBAR Study. · doi.org
- [12]Can Plasma Exchange Be Used to Lower the Circulating Burden of Microplastics in Human Patients? · doi.org
- [13]preliminary double filtration study whose authors include Ayus staff and an advisory board member · doi.org
- [14]Role of Therapeutic Plasma Exchange in Accelerating the Clearance of Perfluoroalkyl and Polyfluoroalkyl Substances. · doi.org
- [15]Plasma exchange therapy for the post COVID-19 condition: a phase II, double-blind, placebo-controlled, randomized trial - Nature Communications · doi.org
- [16]510(k) Premarket Notification · accessdata.fda.gov
- [17]510(k) Premarket Notification · accessdata.fda.gov
- [18]Therapeutic Plasma Exchange | Reborne Longevity · rebornelongevity.com
- [19]Reborne Longevity enters administration · healthclubmanagement.co.uk
For information, not medical advice. Suggest a correction · Editorial policy


